Neurocrine Biosciences, Inc. Share Price
NASDAQ: NBIX | Large CapNeurocrine Biosciences, Inc. Stock Performance
Open $161.30 | Prev. Close $159.92 | Circuit Range N/A |
Day Range $161.30 - $164.51 | Year Range $122.17 - $186.10 | Volume 45,065 |
Average Traded $163.82 |
Neurocrine Biosciences, Inc. Share Price Today
As of 10 August 2026, Neurocrine Biosciences, Inc.'s share price is $163.42. The stock opened at $161.30, compared to its previous close of $159.92. During today's trading session, Neurocrine Biosciences, Inc.'s share price traded between $161.30 and $164.51, with an average price of $162.91. Over the past 52 weeks, the stock has recorded a high of $186.10 and a low of $122.17. In terms of performance, Neurocrine Biosciences, Inc.'s share price has risen by 23.63% over the last six months and is up 17.08% on a year-on-year basis.
Neurocrine Biosciences, Inc. Share Price Chart
Neurocrine Biosciences, Inc. Stock Fundamentals & Key Indicators
Market Cap $16.26B | PE Ratio (TTM) 33.98 | Dividend Yield N/A |
EPS (TTM) $4.81 | Revenue (TTM) $2.86B | Return On Equity (TTM) 14.71% |
Profit Margin 16.73% | Debt to Equity 0.23 | Quarterly Earnings Growth YoY 61.40% |
Neurocrine Biosciences, Inc. Quarterly Profit & Loss
All figures in USD
Neurocrine Biosciences, Inc. Annual Profit & Loss
All figures in USD
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $167.70 | $163.26 | -2.10% |
Jul 2026 | $168.57 | $166.76 | -0.99% |
Jun 2026 | $159.50 | $168.42 | +6.36% |
May 2026 | $132.03 | $158.35 | +20.15% |
Apr 2026 | $132.47 | $131.79 | +0.05% |
Mar 2026 | $131.82 | $131.73 | -0.35% |
Feb 2026 | $136.25 | $132.19 | -2.87% |
Jan 2026 | $141.42 | $136.09 | -4.01% |
Dec 2025 | $151.39 | $141.77 | -6.85% |
Nov 2025 | $143.70 | $152.19 | +6.29% |
Oct 2025 | $139.97 | $143.19 | +2.00% |
Sep 2025 | $140.62 | $140.38 | +0.57% |
NBIX Share Price FAQs
What is Neurocrine Biosciences, Inc. share price today?
What is the 52 week high and 52 week low of Neurocrine Biosciences, Inc. stock?
What is NBIX's market capitalisation today?
What is NBIX's net income for the last quarter?
What is the 5 year returns of NBIX?
What is the high & low stock price of NBIX today?
Can I buy NBIX shares in India?